Patient characteristics (n = 167)
Demographics | |
Age, y | 60 ± 17 |
Sex, male/female, n | 96/74 |
Weight, kg | 84 ± 19 |
Height, cm | 171 ± 10 |
Ethnicity | |
White | 159 (95.2) |
Black | 4 (2.4) |
Asian | 3 (1.8) |
Other | 1 (0.6) |
Prescribed medication | |
Amiodarone | 2 (1.2) |
Statins | 45 (26.9) |
Antiplatelet drugs | 55 (32.9) |
Antibiotics | 6 (3.6) |
Antifungal drugs | 1 (0.6) |
NSAIDs | 12 (7.2) |
Indication for warfarin | |
Atrial fibrillation | 61 (36.6) |
Deep vein thrombosis | 77 (46.1) |
Pulmonary embolism | 21 (12.6) |
Other | 8 (4.7) |
Prescribed warfarin dose | |
Mean maintenance dose, mg/d | 5.54 |
CYP2C9 | |
*1/*1 | 119 (71.3) |
*1/*2 | 29 (17.4) |
*1/*3 | 14 (8.4) |
*2/*2 | 3 (1.7) |
*2/*3 | 2 (1.2) |
*3/*3 | 0 |
VKORC1 −1639 | |
G/G | 66 (39.5) |
G/A | 75 (44.9) |
A/A | 26 (15.6) |
CYP4F2 c.1297 | |
C/C | 80 (48.6) |
C/T | 68 (40.7) |
T/T | 19 (11.3) |
Demographics | |
Age, y | 60 ± 17 |
Sex, male/female, n | 96/74 |
Weight, kg | 84 ± 19 |
Height, cm | 171 ± 10 |
Ethnicity | |
White | 159 (95.2) |
Black | 4 (2.4) |
Asian | 3 (1.8) |
Other | 1 (0.6) |
Prescribed medication | |
Amiodarone | 2 (1.2) |
Statins | 45 (26.9) |
Antiplatelet drugs | 55 (32.9) |
Antibiotics | 6 (3.6) |
Antifungal drugs | 1 (0.6) |
NSAIDs | 12 (7.2) |
Indication for warfarin | |
Atrial fibrillation | 61 (36.6) |
Deep vein thrombosis | 77 (46.1) |
Pulmonary embolism | 21 (12.6) |
Other | 8 (4.7) |
Prescribed warfarin dose | |
Mean maintenance dose, mg/d | 5.54 |
CYP2C9 | |
*1/*1 | 119 (71.3) |
*1/*2 | 29 (17.4) |
*1/*3 | 14 (8.4) |
*2/*2 | 3 (1.7) |
*2/*3 | 2 (1.2) |
*3/*3 | 0 |
VKORC1 −1639 | |
G/G | 66 (39.5) |
G/A | 75 (44.9) |
A/A | 26 (15.6) |
CYP4F2 c.1297 | |
C/C | 80 (48.6) |
C/T | 68 (40.7) |
T/T | 19 (11.3) |
Values are mean ± SD or n (%), unless otherwise indicated.
NSAIDs indicates nonsteroidal anti-inflammatory drugs.